同源康醫藥(02410.HK)訂潛在總代理協議 涉最高1.5億人幣
同源康醫藥-B(02410.HK)公布,公司關連人士之聯繫人「四川匯宇」,已昨日刊發公告,內容有關批准其全資附屬公司「四川匯辰昕」與公司就TY-9591(公司之核心產品)訂立潛在總代理協議,根據潛在總代理安排,公司可同意委任「四川匯辰昕」為TY-9591在中國(不包括香港、澳門、台灣及任何其他海外地區)的獨家總代理商,初始里程碑付款金額最高可達1.5億元人民幣。
公司認為,該安排將有助提升TY-9591的銷售及收入,加快市場滲透,減少集團建立新銷售渠道之成本,並透過與知名藥企合作鞏固集團品牌形象。
TY-9591是一種針對EGFR突變肺癌腦轉移患者開發的酪氨酸激(酉每)抑制劑(TKI),對表皮生長因子受體(「EGFR」)突變肺癌腦轉移患者具有顯著療效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.